The Novel Allosteric NEK7 Inhibitor Ofirnoflast (HT-6184) Demonstrates Robust and Sustained Hematologic Response in Subjects with IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndrome ...

Relay Therapeutics leads with RLY-2608, an allosteric PI3Kα inhibitor showing superior safety and efficacy in advanced breast cancer. RLY-2608’s phase 1/2 trial data demonstrates higher response rates ...

Good morning, everyone, and welcome, everyone, to the Prelude Therapeutics Investor Conference Call. Today's call is being recorded and is expected to last up to 45 minutes. At this time, I will now ...

Biogen gains exclusive rights to Vanqua's oral C5aR1 antagonist, boosting its immunology pipeline with potential across multiple immune diseases.

U.S. net product revenue for the three and nine months ended September 30, 2025 was $40.7 million and $115.8 million, respectively, compared to $31.1 million and $84.2 million, for the comparable ...

Deucravacitinib reduces circulating proteins associated with kidney dysfunction in patients with systemic lupus erythematosus, according to data presented at ACR Convergence 2025.“Specific plasma ...

New study shows that targeting an oft-drugged family of cell membrane receptors with biased modulators can expand potential drug targets and reduce side effects.

Under the subject "The Evolving Field of Cell and Gene Therapy", Cellex Cell Professionals GmbH hosted an international symposium on November 6, 2025, in Frankfurt/Main. More than 100 participants ...

- SUDO-550 demonstrated favorable safety, tolerability, and once-daily pharmacokinetic profile with full central nervous system (CNS) penetration - Achieved exposure levels associated with >90% ...